These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30868391)

  • 21. Correlation of PKM2 Expression With HER2/neu and Additional Breast Cancer Biomarkers and its Prognostic Significance.
    Al-Qudah MA; Al-Keilani MS; Obeidat M; Haddad HK; Bdeir R; Samman LM
    Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):363-370. PubMed ID: 37212690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
    Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
    J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
    Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
    Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
    Nitz U; Gluz O; Christgen M; Kates RE; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Lorenz-Salehi F; Krabisch P; Just M; Augustin D; Liedtke C; Chao C; Shak S; Wuerstlein R; Kreipe HH; Harbeck N
    Breast Cancer Res Treat; 2017 Oct; 165(3):573-583. PubMed ID: 28664507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.
    Schmidt G; Meyberg-Solomayer G; Gerlinger C; Juhasz-Böss I; Herr D; Rody A; Liedtke C; Solomayer EF
    Arch Gynecol Obstet; 2014 Dec; 290(6):1221-9. PubMed ID: 25012601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.
    Haroon S; Hashmi AA; Khurshid A; Kanpurwala MA; Mujtuba S; Malik B; Faridi N
    Asian Pac J Cancer Prev; 2013; 14(7):4353-8. PubMed ID: 23992002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic significance of Ki-67 expression before and after neoadjuvant chemotherapy in different biological breast cancer phenotypes].
    Liu Y; Zhang X; Yu F; Liu J; Zhang M; Zhang S; Hao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):671-6. PubMed ID: 25564057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
    Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
    Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histogram analysis of apparent diffusion coefficient at 3.0t: Correlation with prognostic factors and subtypes of invasive ductal carcinoma.
    Kim EJ; Kim SH; Park GE; Kang BJ; Song BJ; Kim YJ; Lee D; Ahn H; Kim I; Son YH; Grimm R
    J Magn Reson Imaging; 2015 Dec; 42(6):1666-78. PubMed ID: 25919239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
    Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
    Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer.
    Zhu X; Chen L; Huang B; Wang Y; Ji L; Wu J; Di G; Liu G; Yu K; Shao Z; Wang Z
    Sci Rep; 2020 Jan; 10(1):225. PubMed ID: 31937819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.